Kidney disease therapy could treat glaucoma

Article

The diuretic agents, vasopressin-receptor antagonists, or vaptans, may have a use in the treatment of glaucoma, according to a study appearing in the 10 May, 2008 issue of The Lancet.

The diuretic agents, vasopressin-receptor antagonists, or vaptans, may have a use in the treatment of glaucoma, according to a study appearing in the 10 May, 2008 issue of The Lancet.

A team led by Professor Guy Decaux of Erasmus University Hospital, Brussels, Belgium, found that vaptans, taken orally or intravenously, exerts their effect by competing with vasopressin hormone molecules thus blocking the action of the natural hormone vasopressin.

Currently available vaptans have been developed to treat diseases, such as dysmenorrhoea, Raynaud's disease, renal failure, and diabetic nephropathy. However, this class of agents have also shown promise in preliminary studies for the treatment of glaucoma and further investigation is now warranted to establish whether they have a true role in the treatment of this ocular condition.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.